Business Description
PharmaResearch Co Ltd
ISIN : KR7214450009
Compare
Compare
Traded in other countries / regions
214450.Korea IPO Date
2015-07-24Description
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.78 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 0.31 | |||||
| Interest Coverage | 30.88 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 12.89 | |||||
| Beneish M-Score | -2.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.8 | |||||
| 3-Year EBITDA Growth Rate | 29.5 | |||||
| 3-Year EPS without NRI Growth Rate | 25.4 | |||||
| 3-Year Book Growth Rate | 18.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.91 | |||||
| 9-Day RSI | 72.23 | |||||
| 14-Day RSI | 70.89 | |||||
| 6-1 Month Momentum % | -17.76 | |||||
| 12-1 Month Momentum % | -10.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.89 | |||||
| Quick Ratio | 3.13 | |||||
| Cash Ratio | 2.43 | |||||
| Days Inventory | 198.76 | |||||
| Days Sales Outstanding | 45.28 | |||||
| Days Payable | 24.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.74 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | 23.9 | |||||
| Forward Dividend Yield % | 0.74 | |||||
| 5-Year Yield-on-Cost % | 2.43 | |||||
| 3-Year Average Share Buyback Ratio | -1.8 | |||||
| Shareholder Yield % | 1.9 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.89 | |||||
| Operating Margin % | 35.35 | |||||
| Net Margin % | 29.33 | |||||
| FCF Margin % | 19.83 | |||||
| ROE % | 19.75 | |||||
| ROA % | 15.04 | |||||
| ROIC % | 23.9 | |||||
| ROC (Joel Greenblatt) % | 59.05 | |||||
| ROCE % | 21.17 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.86 | |||||
| PE Ratio without NRI | 16.65 | |||||
| Shiller PE Ratio | 40.84 | |||||
| Price-to-Owner-Earnings | 20.44 | |||||
| PEG Ratio | 0.45 | |||||
| PS Ratio | 5.05 | |||||
| PB Ratio | 2.98 | |||||
| Price-to-Tangible-Book | 3.2 | |||||
| Price-to-Free-Cash-Flow | 25.42 | |||||
| Price-to-Operating-Cash-Flow | 20.26 | |||||
| EV-to-EBIT | 12.06 | |||||
| EV-to-EBITDA | 10.73 | |||||
| EV-to-Revenue | 4.46 | |||||
| EV-to-FCF | 22.62 | |||||
| Price-to-Projected-FCF | 2.05 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.67 | |||||
| Price-to-Graham-Number | 1.54 | |||||
| Price-to-Net-Current-Asset-Value | 8.33 | |||||
| Price-to-Net-Cash | 22.11 | |||||
| Earnings Yield (Greenblatt) % | 8.29 | |||||
| FCF Yield % | 4.03 | |||||
| Forward Rate of Return (Yacktman) % | 22.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaResearch Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 261,010.912 | ||
| EPS (TTM) (â‚©) | 7479 | ||
| Beta | 0.86 | ||
| Volatility % | 58.36 | ||
| 14-Day RSI | 70.89 | ||
| 14-Day ATR (â‚©) | 7184.161095 | ||
| 20-Day SMA (â‚©) | 110335 | ||
| 12-1 Month Momentum % | -10.18 | ||
| 52-Week Range (â‚©) | 86800 - 158200 | ||
| Shares Outstanding (Mil) | 10.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaResearch Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaResearch Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaResearch Co Ltd Frequently Asked Questions
What is PharmaResearch Co Ltd(XKRX:214450)'s stock price today?
The current price of XKRX:214450 is â‚©126100.00. The 52 week high of XKRX:214450 is â‚©158200.00 and 52 week low is â‚©86800.00.
When is next earnings date of PharmaResearch Co Ltd(XKRX:214450)?
The next earnings date of PharmaResearch Co Ltd(XKRX:214450) is .
Does PharmaResearch Co Ltd(XKRX:214450) pay dividends? If so, how much?
The Dividend Yield %  of PharmaResearch Co Ltd(XKRX:214450) is 0.74% (As of Today), Highest Dividend Payout Ratio of PharmaResearch Co Ltd(XKRX:214450) was 0.27. The lowest was 0.13. And the median was 0.14. The  Forward Dividend Yield % of PharmaResearch Co Ltd(XKRX:214450) is 0.74%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers